// App-Quantinova.ai

: Immunomodulatory response to neoadjuvant nivolumab in non-metastatic clear cell renal cell carcinoma.

Researchers

Presenter

  • Nirmish Singla

Principal Investigators

  • Aleksandar Obradovic

  • Eugene Shenderov

  • Kara A. Lombardo

  • Xiaopu Liu

  • Alice Pons

  • Jelani Zarif

  • Steven P. Rowe

  • Bruce J. Trock

  • Hans J. Hammers

  • Trinity Bivalacqua

  • Phillip Pierorazio

  • Julie S. Deutsch

  • Tamara L. Lotan

  • Janis M. Taube

  • Yasser Ged

  • Michael A. Gorin

  • Mohamad E. Allaf

  • Charles G. Drake

Medical Centers

  • Johns Hopkins University, Baltimore, MD

  • Columbia University, New York, NY

  • James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD

  • University of Pennsylvania Medical Center, Philadelphia, PA

  • Janssen R&D Oncology, New Hope, PA

  • UTSouthwestern Medical Center, Dallas, TX

  • Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA

  • The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD

  • Johns Hopkins Hosp School of Medcn, Baltimore, MD

  • Icahn School of Medicine at Mount Sinai, New York, NY

  • Johns Hopkins University - The Brady Urological Institute, Baltimore, MD

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Clear cell renal carcinoma

Biomarkers

  • N/A

Drug/Treatment

  • Nivolumab

Outcome

  • N/A

Study Design

  • Prospective

  • Cohort

Phase

  • I

Study Id's

  • NCT02575222

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved